Whitehawk Therapeutics, Inc.
Ownership
Ownership Structure
Who owns Whitehawk Therapeutics, Inc. (WHWK)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 50.4% of the shares are freely tradable; institutional investors hold 72.5%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Longwood Capital Partners LLC | 8.22 | 4,685,912 | +37.4 | 06/30/2026 |
| Qvt Financial LP | 8.10 | 4,615,709 | +0.0 | 06/30/2026 |
| Orbimed Advisors LLC | 7.31 | 4,166,000 | +0.0 | 03/31/2026 |
| Suvretta Capital Management, LLC | 6.49 | 3,700,000 | +0.0 | 03/31/2026 |
| venBio Select Advisor LLC | 5.00 | 2,849,402 | +0.0 | 03/31/2026 |
| KVP Capital Advisors, LP | 3.80 | 2,165,997 | +0.0 | 06/30/2026 |
| Siren, L.L.C. | 3.65 | 2,082,000 | +0.0 | 03/31/2026 |
| Yu Fan | 3.63 | 2,070,000 | +0.0 | 03/31/2026 |
| StemPoint Capital LP | 3.30 | 1,878,738 | +28.8 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.31 | 1,315,770 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Dalal Anupam | Director | 4,685,912 | 19,212,239 $ | May 14, 2026 | indirect |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | Dalal Anupam | Director | Other | 1,275,510 | 3.92 | 4,999,999 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.